Uma Thanarajasingam
YOU?
Author Swipe
View article: Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies Open
Immune checkpoint inhibitor (ICI)–induced inflammatory arthritis (IA) is an increasingly recognized immune-related adverse event (irAE), yet its underlying immunopathogenesis remains poorly understood. Unlike rheumatoid arthritis (RA), whe…
View article: COMPLEMENTARY LUPUS-SPECIFIC INDEXES INFORMED BY SELECT IMMUNE MEDIATORS CHARACTERIZE RISK OF CONCURRENT DISEASE ACTIVITY AND FUTURE IMPENDING FLARE IN SYSTEMIC LUPUS ERYTHEMATOSUS
COMPLEMENTARY LUPUS-SPECIFIC INDEXES INFORMED BY SELECT IMMUNE MEDIATORS CHARACTERIZE RISK OF CONCURRENT DISEASE ACTIVITY AND FUTURE IMPENDING FLARE IN SYSTEMIC LUPUS ERYTHEMATOSUS Open
PT002 / #417 Topic: AS09 - Emerging Approaches in SLE Management POSTER TOUR 01: CLINICAL OUTCOMES IN SLE 22-05-2025 10:00 AM - 10:40 AM Background/Purpose Systemic lupus erythematosus (SLE) is driven by immune dysregulation, with increase…
View article: Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with Neuroendocrine Carcinoma Undergoing Immune Checkpoint Inhibitor Cancer Immunotherapy
Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with Neuroendocrine Carcinoma Undergoing Immune Checkpoint Inhibitor Cancer Immunotherapy Open
This case highlights the challenges of managing pre-existing PNS during ICI therapy, emphasizing the need for a multidisciplinary approach and the consideration of unusual clinical presentations in therapeutic decision-making.
View article: Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network
Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network Open
Objectives The objectives of this study were to assess the prevalence and incidence of multimorbidity and its association with the SLICC/ACR damage index (SDI) among patients with SLE. Methods Using prevalent and incident population–based …
View article: Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients Open
Introduction The longitudinal responses towards multiple doses of COVID-19 mRNA vaccines in patients with systemic autoimmune diseases remain incompletely understood. While observational studies suggested the safety of COVID-19 mRNA vaccin…
View article: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events Open
Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evalu…
View article: Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients Open
Objective To evaluate seroreactivity and disease biomarkers after 2 or 3 doses of COVID-19 mRNA vaccines in a cohort of patients with rheumatic diseases. Methods We collected biological samples longitudinally before and after 2-3 doses of …
View article: 626 The trajectory of Multimorbidity in patients with Systemic Lupus Erythematosus in the United States
626 The trajectory of Multimorbidity in patients with Systemic Lupus Erythematosus in the United States Open
Background/Purpose The presence of multiple chronic conditions (multimorbidity) is associated with disability and premature death. We determined the trajectory of multimorbidity in SLE compared to the general population. Methods An SLE coh…
View article: A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus
A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus Open
Objective Systemic lupus erythematosus (SLE) is marked by immune dysregulation linked to varied clinical disease activity. Using a unique longitudinal cohort of SLE patients, this study sought to identify optimal immune mediators informing…
View article: 816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
816 Selective immune suppression using interleukin-6 blockade in immune related adverse events Open
Background Managing immune-related adverse events (irAEs) has become a critical challenge with the increasing implementation of immune-checkpoint inhibitors (ICIs) in cancer treatment. IrAEs may cause treatment interruption or discontinuat…
View article: Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department
Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department Open
Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of cancer. Immune checkpoint inhibitors may cause a wide-range of autoimmune toxicities referred to as immune-related adverse events (irAEs). There is a paucity of …
View article: Immune‐related hematologic adverse events in the context of immune checkpoint inhibitor therapy
Immune‐related hematologic adverse events in the context of immune checkpoint inhibitor therapy Open
To the Editor: Immune checkpoint inhibitors (ICI), such as antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligand (PD-L1), are increasingly used in the treatment …
View article: Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis Open
Objective The objective of this study was to describe differences in the clinical course of patients with rheumatoid arthritis (RA) who are antinuclear antibody (ANA)–positive compared with those who are ANA‐negative. Methods This was a re…
View article: Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus
Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus Open
Objective Type I interferon (IFN) is important to systemic lupus erythematosus (SLE) pathogenesis, but it is not clear how chronic elevations in IFN alter immune function. We compared cytokine responses after whole blood stimulation with T…
View article: Differential Expression of Interferon-Induced Genes and Other Tissue-Based Acute Gvhd Biomarkers in Acute Gvhd Compared to Lupus Erythematosus in Skin
Differential Expression of Interferon-Induced Genes and Other Tissue-Based Acute Gvhd Biomarkers in Acute Gvhd Compared to Lupus Erythematosus in Skin Open
Background: The pathogenesis of both acute graft-versus-host disease (GVHD) and lupus erythematosus (LE) involves an immunologic assault on a patient's own tissues via complex mechanisms influenced by type I interferons and other cytokines…
View article: Brief Report: A Novel <i>ELANE</i> Mutation Associated With Inflammatory Arthritis, Defective NETosis, and Recurrent Parvovirus Infection
Brief Report: A Novel <i>ELANE</i> Mutation Associated With Inflammatory Arthritis, Defective NETosis, and Recurrent Parvovirus Infection Open
Objective We describe a 38‐year‐old woman who presented with a history of inflammatory arthritis, rash, and daily fevers. She was noted to have chronic parvovirus infection with persistently detectable viral titers and a novel mutation in …